CD3

CD3 bridges the gap between innovative biomedical research emerging from academic institutes or biotechs and the pharmaceutical industry, and create value for all stakeholders.

The Centre for Drug Design and Discovery (CD3), based in Leuven (Belgium), is a drug discovery centre and investment fund created to drive the translation of innovative basic research to the clinic. As investment fund, CD3 can invest in drug discovery projects as well as in spin-off companies and biotechs, while as drug discovery centre, it complements investments with an experienced drug discovery team and state-of-the-art infrastructure. The cornerstone of CD3’s activities are hand-in-hand collaborations with academic research groups and biotech or pharma partners, always aimed at discovering and developing new medicines. Successful collaborations lead to partnering with biotech or pharma or the creation of spin-off companies.

CD3 was set up in 2006 by KU Leuven Research & Development (LRD) and the European Investment Fund (EIF). In 2016, CD3 launched a third fund of 60 million euro to broaden its scope and extend its capabilities. In addition to investing in collaborative drug discovery projects with academic research groups, CD3 invests in drug discovery start-ups and biotech companies. As an investment fund with an experienced drug discovery team at hand, CD3 provides these companies with invaluable guidance and support in their start up and growth process.

CD3 focuses on the discovery and development of innovative medicines for all kinds of diseases by building further on the enormous pool of innovative research and technologies of universities and spin-off companies. 

Applicants willing to get in touch with CD3 can do it by following this link.

Portfolio: Gilead Sciences, Biohaven, Aligos, Novartis.